Investor Presentaiton

CD28 pathway's central role is validated by current approved immunotherapies CTLA-4 regulatory pathway: Competition on CD80/86 binding BIOND BIOLOGICS CD80/CD86 CD28 APC CTLA-4 (higher affinity to CD80/86 molecules) T cell inhibition Anti-CTLA4 blocking antibody Approved in melanoma and RCC PD-1 regulatory pathway: suppression by dephosphorylation of CD28 CD80/CD86 PD-L1 CD28 PD-1 SHP-2 T cell inhibition Biond Biologics Corporate Presentation | May 2021 | Non-confidential APC Anti-PD1 blocking antibody Approved in multiple tumor types e.g., melanoma, lung, RCC, H&N, HCC, bladder 16

View entire presentation